The AP (12/31) reported that under "a national agreement that resolves allegations of improper off-label marketing of three drugs," pharmaceutical manufacturer Cephalon, Inc. "will pay $425 million to federal and state Medicaid programs." As part of the settlement, Montana received nearly "$157,000 in Medicaid restitution and penalties."
In a separate article, the AP (12/31) added that "Cephalon has paid more than $2.6 million to" Nebraska under the settlement, according to Attorney General Jon Bruning. The AP (12/31) noted in a third article that the drugmaker also agreed to pay Massachusetts $4.7 million. The allegations surrounded marketing of "Actiq (fentanyl oral transmucosal), a highly addictive painkiller; the anti-seizure drug Gabitril (tiagabine); and the sleep-disorder drug Provigil (modafinil)."
Copyright © 2008 by Custom Briefings | 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191